Literature DB >> 32259779

Including DPYD on Cancer Genetic Panels to Prevent Fatal Fluoropyrimidine Toxicity.

Daniel L Hertz, Vaibhav Sahai.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32259779     DOI: 10.6004/jnccn.2019.7527

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


× No keyword cloud information.
  6 in total

1.  Comparison of clinical pharmacogenetic recommendations across therapeutic areas.

Authors:  Tyler Shugg; Amy L Pasternak; Jasmine A Luzum
Journal:  Pharmacogenet Genomics       Date:  2022-02-01       Impact factor: 2.089

Review 2.  Modern developments in germline pharmacogenomics for oncology prescribing.

Authors:  Natalie M Reizine; Peter H O'Donnell
Journal:  CA Cancer J Clin       Date:  2022-03-18       Impact factor: 286.130

3.  Survey of US Medical Oncologists' Practices and Beliefs Regarding DPYD Testing Before Fluoropyrimidine Chemotherapy.

Authors:  Kyoin Koo; Amy L Pasternak; N Lynn Henry; Vaibhav Sahai; Daniel L Hertz
Journal:  JCO Oncol Pract       Date:  2022-03-03

4.  The Value of Pharmacogenetics to Reduce Drug-Related Toxicity in Cancer Patients.

Authors:  Doreen Z Mhandire; Andrew K L Goey
Journal:  Mol Diagn Ther       Date:  2022-02-03       Impact factor: 4.074

5.  Defining Clinical Utility of Germline Indicators of Toxicity Risk: A Perspective.

Authors:  Daniel L Hertz; Lisa M McShane; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2022-03-24       Impact factor: 50.717

Review 6.  DPYD and UGT1A1 Pharmacogenetic Testing in Patients with Gastrointestinal Malignancies: An Overview of the Evidence and Considerations for Clinical Implementation.

Authors:  Lisa A Varughese; Kelsey S Lau-Min; Christine Cambareri; Nevena Damjanov; Ryan Massa; Nandi Reddy; Randall Oyer; Ursina Teitelbaum; Sony Tuteja
Journal:  Pharmacotherapy       Date:  2020-10-19       Impact factor: 6.251

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.